Cargando…
Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068739/ https://www.ncbi.nlm.nih.gov/pubmed/32201507 http://dx.doi.org/10.1177/1758835920913426 |